Evogene (EVGN) Tops Q4 EPS by 13c

Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.07), $0.13 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $660 thousand versus the consensus estimate of $425 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c